Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 18/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 10/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780530 | 1.00 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1780185 | 0.92 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL5331775 | 0.90 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL29352331 | 0.90 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267696 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267728 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1779543 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1781336 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267743 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267749 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626494-A1 | LYOPHILIZED AND SPRAYABLE SILK FIBROIN AND MODIFIED SILK FIBROIN FORMS | Evolved by Nature, Inc. (US) | 2025-10-08 | — | — | EP | claimed |
| EP-4587635-A2 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | Evolved by Nature, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| WO-2024059862-A9 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2025-04-24 | — | — | WO | claimed |
| WO-2024119107-A1 | LYOPHILIZED AND SPRAYABLE SILK FIBROIN AND MODIFIED SILK FIBROIN FORMS | EVOLVED BY NATURE, INC. (US) | 2024-06-06 | — | — | WO | claimed |
| WO-2024059862-A2 | FIBROIN PEPTIDES AND PROTEIN FRAGMENTS COMPOSITIONS | EVOLVED BY NATURE, INC. (US) | 2024-03-21 | — | — | WO | claimed |
| CN-122063624-A | RSSI (received signal strength indicator) driving-based self-adaptive time-sharing multimode positioning method | 国家林业和草原局西北调查规划院 | 2026-05-19 | — | — | CN | disclosed |
| CN-122043356-A | Three-dimensional positioning method and system for bimodal targets | 江南大学 | 2026-05-15 | — | — | CN | disclosed |
| CN-121679365-B | Battery SOC online simulation method and device, electronic equipment and storage medium | 深圳清华大学研究院 | 2026-05-15 | — | — | CN | disclosed |
| EP-4703470-A1 | CELLULASE VARIANTS | AB Enzymes Finland Oy (FI) | 2026-03-04 | — | — | EP | disclosed |
| EP-4626494-A1 | LYOPHILIZED AND SPRAYABLE SILK FIBROIN AND MODIFIED SILK FIBROIN FORMS | Evolved by Nature, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250277211-A1 | LPA inhibitors and uses thereof | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2025-09-04 | — | — | US | disclosed |
| EP-4610356-A1 | RNA INHIBITOR FOR INHIBITING LPA GENE EXPRESSION AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| CN-112850696-B | Transfer method of graphene film, graphene film and graphene composite structure | 北京石墨烯研究院 | 2022-11-22 | — | — | CN | disclosed |
| CN-115336204-A | Downlink Control Information (DCI) on Physical Downlink Shared Channel (PDSCH) | 高通股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-115336219-A | Enabling Remaining Minimum System Information (RMSI) repetition or RMSI slot aggregation | 高通股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-11478501-B2 | Compositions and methods for inhibiting HMGB1 expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-11446383-B2 | Lipid formulations for delivery of therapeutic agents | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-09-20 | — | — | US | disclosed |
| CN-115004578-A | Handover mechanism for non-terrestrial network (NTN) systems in 5G New Radios (NR) | 高通股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-114703184-A | LPA inhibitor and use thereof | 厦门甘宝利生物医药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220186238-A1 | DIPLOSPORY GENE | KEYGENE N.V. (NL) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446383-B2 | Lipid formulations for delivery of therapeutic agents | CETP, PNLIP, NPC1L1 | ADORA2B 3274/4885ADORA1 2210/4885ADORA2A 2686/4885 |
| US-11478501-B2 | Compositions and methods for inhibiting HMGB1 expression | HMGB1, HMGB3, HMGB2 | ADORA2B 2012/4885ADORA1 2825/4885ADORA2A 1696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.